The information found on this site is the personal opinion of the authors, and is intended to educate and interest, rather than to direct clinical management for specific patients. Copyright is shared between the author/s and this site. You may reproduce this content as long as the original source is credited. No information on this site may be reproduced for profit.

Table summarising studies – NMS in asthma

Study Location Year Participants       

(Age; Number)

Randomisation groups Outcomes measured Results
Alansari(36) Qatar 2015 2-14y; n=365 Intervention: NMS (800mg) & BA & IB

Control: Saline & BA & IB

Readiness for discharge, Mg levels Shortened time to reach readiness for discharge with NMS (NS); increased Mg levels
Aggarwal(26) India 2006 13-60y; n=100 Intervention: NMS (1ml, 500mg) & BA – 3 doses 20 mins apart

Control: BA – 3 doses 20 mins apart

PEFR, admissions, physiological parameters, Mg levels Improved PEFR in both groups (no difference between groups); no change in Mg level
Ashtekar(28) UK 2008 2-16y; n=17 Intervention: NMS (2.5ml) & BA & IB – 3 doses 20 mins apart

Control: BA & IB – 3 doses 20 mins apart

Asthma severity score, LOS No significant effect
Badawy(37) USA 2016 7-18y; n=50 Intervention: BA & NMS (22ml, 880mg) – over 1 hour

Control: BA & saline – over 1 hour

FEV1, Paediatric asthma severity score, LOS Awaited
Dadhich(30) India 2003 Age unknown; n=71 Intervention 1: NMS

Intervention 2: NMS & BA

Control: BA

(doses not given)

PEFR, FEV1, FVC, physiological parameters Improved lung function with NMS (NS); greatest effect if PEFR <50%; no change in parameters
Daengsuwan(38) Thailand 2016 2-15y; n=40 Intervention: NMS (2.5ml, 150mg) – 3 doses 20 minutes apart

Control: IV magnesium sulphate (50mg/kg) over 20 minutes

Asthma severity score, LOS Awaited
Drobina(31) USA 2006 12-60y; n=110 Intervention: NMS (150mg) & BA & IB

Control: BA & IB

PEFR Improved PEFR in both groups; trend toward greater improvement with NMS (NS)
Goodacre(39) UK 2013 >16y; n=1109 Intervention 1: IV magnesium sulphate (2g) & BA

Intervention 2: NMS (500mg) & BA – 3 doses 20 minutes apart

Control: BA

Admission rate (7 days), breathlessness using 100mm visual analogue scale (VAS) No difference in 7-day admission rate with NMS; trend toward improved VAS vs placebo with NMS (NS)
Hughes(40) New Zealand 2003 16-65y; n=52 Intervention: NMS (2.5ml; 151mg) & BA – 3 doses 30 minutes apart

Control: BA & saline – 3 doses 30 minutes apart

FEV1 Improved FEV1 with NMS
Khashabi(27) Iran 2008 Mean age 3.55y; n=40 Intervention: NMS (2.5ml) & BA

Control: Saline & BA

Respiratory distress score, LOS, length of O2 requirement Reduced duration of O2 requirement; trend toward improved respiratory distress score & shorter LOS with NMS (both NS)
Mahajan(25) USA 2004 5-17y; n=62 Intervention: NMS (2.5ml) & BA

Control: Saline & BA

FEV1, admission rate Improved FEV1 with NMS; no difference in admission rate
Mangat(23) India 1998 12-60y; n=33 Intervention: NMS (3ml) – 4 doses 20 minutes apart

Control: BA – 4 doses 20 minutes apart

Fischl index, PEFR Improved Fischl index & PEFR in both groups (no difference between groups)
Meral(24) Turkey 1996 Mean age 10.6-11y; n=40 Intervention: NMS (2ml)

Control: BA

Davis-Leffert-Dabbous respiratory distress score, PEFR Improved score & PEFR in both groups (no difference between groups); effect persisted for 6h in control & 1h with NMS
Mohammadzadeh(41) Iran 2014 Children – ages unknown; n=80 Intervention: NMS & BA – up to 3 doses every 20 minutes

Control: BA & saline – up to 3 doses every 20 minutes

Mean pulmonary index, PEFR NMS group had significantly better pulmonary index & PEFR at 90 mins
Neki(29) India 2006 15-60y; n=40 Intervention: NMS – 4 doses 20 minutes apart

Control: BA – 4 doses 20 minutes apart

PEFR, Fischl index Inferior improvement of PEFR with NMS; trend toward improved Fischl index with NMS (NS)
Powell(42) UK 2013 2-16y; n=508 Intervention: NMS (2.5ml; 151mg) & BA & IB – 3 doses 20 minutes apart

Control: Saline & BA & IB – 3 doses 20 minutes apart

Yung Asthma Severity Score (ASS) Improved ASS with NMS; Greater effect with more severe exacerbation & shorter duration of symptoms (<6h)
Saucedo(43) Mexico 2016 2-15y; n=152 Intervention: NMS (2.5ml, 150mg) & BA & IB – every 20 minutes for 1st hour, then hourly as required

Control: Saline & BA & IB – every 20 minutes for 1st hour, then hourly as required

PRAM, O2 saturations, admission rate, clinical parameters Awaited
Schuh(44) Canada Closes 2017 2-17y; n=816 Intervention: NMS (600mg) & BA – 3 doses 20 minutes apart

Control: BA & saline – 3 doses 20 minutes apart

Hospitalisation rate, change in PRAM, BA requirement Awaited
Watanathan(45) Thailand 2015 Mean age 5.5y; n=12 Intervention 1: NMS

Intervention 2: IV magnesium sulphate

(doses not given; no obvious control)

Wood asthma severity score. LOS No significant difference between groups
The information found on this site is the personal opinion of the authors, and is intended to educate and interest, rather than to direct clinical management for specific patients. Copyright is shared between the author/s and this site. You may reproduce this content as long as the original source is credited. No information on this site may be reproduced for profit. 2018, paediatricfoam.com